Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 352 of the 356 references it cites were found in a registry or an index; none of the 390 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCOS). PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We suggest using the Rotterdam criteria for diagnosing PCOS (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCOS is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCOS. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCOS. The role of weight loss in improving PCOS status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk-benefit ratio overall, and statins require further study.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends using the Rotterdam criteria to diagnose PCOS in adults and emphasizes excluding mimics and assessing associated metabolic, cardiovascular, endometrial, mood, and sleep morbidity. It recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne, clomiphene (or comparable estrogen modulators) as first-line therapy for anovulatory infertility, and metformin for T2DM/IGT or as second-line therapy for menstrual irregularity when hormonal contraceptives cannot be used.
Key findings
- PCOS diagnosis in adults should be made if two of three Rotterdam criteria are met—androgen excess, ovulatory dysfunction, or polycystic ovaries—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia; in adolescents, diagnosis should require clinical and/or biochemical hyperandrogenism plus persistent oligomenorrhea, because anovulatory symptoms and PCO morphology are not sufficient.
- Women with PCOS are at increased risk for impaired glucose tolerance and type 2 diabetes: the guideline states a 5- to 10-fold increased risk of developing T2DM, with overall glucose intolerance prevalence of 30–35% and T2DM in 3–10%; nonobese women with PCOS had 10–15% IGT and 1–2% T2DM.
- Hirsutism is present in approximately 65–75% of patients with PCOS, and PCOS represents the major cause of hirsutism; in a large study of patients with clinical hyperandrogenism, 72.1% of 950 patients were diagnosed with PCOS.
- Endometrial cancer risk is increased: a 31-year UK follow-up showed a 3.5 increased relative risk, and a meta-analysis reported RR = 2.7 (95% CI, 1.0–7.29), confirmed by a subsequent systematic review with a 3-fold increased risk.
- Depression and sleep-disordered breathing are also increased: one study reported major depression episode/recurrent depression OR 3.8 (95% CI, 1.5–8.7; P = .001) and suicide attempts seven times higher in PCOS cases vs controls; women with PCOS were 30 times more likely to have sleep-disordered breathing and nine times more likely to have daytime sleepiness after controlling for BMI.
Methods
- An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline using the GRADE system to describe recommendation strength and evidence quality.
- Consensus was reached through one group meeting, several conference calls, and e-mail communications; committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts.
- Two systematic reviews were conducted to summarize supporting evidence; recommendations use “we recommend” with number 1 for strong recommendations and “we suggest” with number 2 for weak recommendations, with cross-filled circles indicating evidence quality.
Limitations
- The guideline states that there are no adequately powered, randomized, double-blind, placebo-controlled trials in adolescents with PCOS; no large randomized trials of exercise in PCOS; and no long-term data assessing the effect of hormonal contraceptives on glucose tolerance in nondiabetic and diabetic women with PCOS.
- It states that there are currently no diagnostic criteria for PCOS in perimenopausal and menopausal women, no age-related testosterone cutoffs, and that testosterone assays used to diagnose hyperandrogenemia in women are imprecise.
- It notes that the Rotterdam ultrasound PCO criteria were not validated for adolescents, that there is a lack of well-defined cutoff points for androgen levels during normal pubertal maturation, and that many recommendations are weak because evidence is limited or inconclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 201 Not checked · 50 Own results and interpretations
In the paper
“However, hirsutism was a major symptom in about 60% of adolescents in one study (27) and may be suggestive of PCOS in adolescents (28).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Diagnosis of PCOS
What the sources say
- Not checked yetcites [27] Pfeifer SM, Kives S Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009; 36: 129– 152. 19344852
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but our systematic review did not confirm this (211).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [211] Domecq JP, Prutsky G, Mullan R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013–2385. 24092832
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“although there were significant improvements in some metabolic parameters (mainly glycemic effects related to improvements in fasting blood glucose and insulin levels) (249, 250).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found little evidence to support lifestyle change as an infertility treatment”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our own meta-analysis showed that weight loss had minimal effects on hirsutism and fertility”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
146 more claims
Create a free account to see all 252 claims and to verify the 390 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al. , 2011; Legro et al. , 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the interim there is inadequate evidence on the impact of metformin on glucose tolerance in prediabetes and DM2 specifically in PCOS, but based on data in general populations, current guidelines recommend using metformin in obese women with PCOS who have prediabetes or DM2 (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al. , 2013
Experimental — accuracy not yet measuredIn the citing paper
“It is indicated in combination with COCs, especially for overweight or obese patients, or when COCs are contraindicated [46].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [46]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“implementation of evidence-based guidelines (4).”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationThe diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Overall, hirsutism is present in approximately 65–75% of patients with PCOS (although lower in Asian populations) (15, 52).”
BackgroundPhysical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women
Blair, S. N. (1989) · JAMA · doi:10.1001/jama.1989.03430170057028 · Cited by 2,658 · cited 1×
“diovascular fitness, as measured by maximal oxygen consumption during exercise, is an independent predictor of cardiovascular mortality (229).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause transition per se (43…”
BackgroundSelf-citation
Research works printed but not linked: 1
- [286]Tanner JM Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed Philadelphia, PA: WB Saunders: 1975: 14.
Cited by
Items 501–600 of 1,004
Faienza, M. F., Brunetti, G., Acquafredda, A., Delvecchio, M., Lonero, A., Gaeta, A., Suavo-Bulzis, P., Corica, D., Velletri, M. R., Luca, F. D., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000456546 · Cited by 37
Lo, J. C.-M., Yang, J., Gunderson, E. P., Hararah, M. K., Gonzalez, J. R., & Ferrara, A. M. (2017) · Journal of Diabetes Research · doi:10.1155/2017/5250162 · Cited by 37
“Collectively, these findings emphasize the importance of systematic diabetes screening in this high-risk population [1] and further studies examining racial/ethnic differences in the outcome, the role of androgen excess, weight status, and modifiable risk factors.”
BackgroundWanderley, M. D. S., Pereira, L. C. R., Santos, C. B., da Cunha, V. S., & Neves, M. V. J. (2018) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0038-1642634 · Cited by 37
Wang, F., Pan, J., Wu, Y. T., Zhu, Y., Hardiman, P., & Qu, F. (2018) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1700074 · Cited by 37
“In dealing with the overweight and obesity, all three guidelines/consensuses recommend calorierestricted diets and exercise (The Rotterdam ESHRE/ ASRM-Sponsored PCOS Consensus Workshop Group, 2004a, 2004b; Endocrinology Group et al., 2008; The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008a, 200…”
BackgroundMethodInfluentialSchneider, D. L., Gonzalez, J. R., Yamamoto, M. P., Yang, J., & Lo, J. C.-M. (2019) · Journal of Pregnancy · doi:10.1155/2019/9847057 · Cited by 37
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Pandurevic, S., Mancini, I., Mitselman, D., Magagnoli, M., Teglia, R., Fazzeri, R., Dionese, P., Cecchetti, C., Caprio, M., Moretti, C., et al. (2023) · Endocrine Connections · doi:10.1530/ec-22-0536 · Cited by 36
Yu, T., Wu, D., Cao, Y., & Zhai, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.740377 · Cited by 36
Metformin: Sex/Gender Differences in Its Uses and Effects—Narrative Review
Ilias, Ι., Rizzo, M., & Zabulienė, L. (2022) · Medicina · doi:10.3390/medicina58030430 · Cited by 36
“In 2013, the American Endocrine Society issued guidelines on the management of PCOS which included MTF as a treatment [24].”
BackgroundGupta, M., Yadav, P., & Yaqoob, F. (2022) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-022-01704-0 · Cited by 36
Gourgari, E., Lodish, M. B., Shamburek, R. D., Keil, M. F., WESLEY, R. A., Walter, M. F., Sampson, M. L., Bernstein, S. B., Khurana, D., Lyssikatos, C., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2566 · Cited by 37
“Other comorbidities include obesity, insulin resistance, and a higher risk for diabetes, cardiovascular disease, gestational diabetes, infertility, and metabolic syndrome (1).”
BackgroundMethodPolycystic Ovary Syndrome in Adolescents
Witchel, S. F., Roumimper, H., & Oberfield, S. E. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.01.004 · Cited by 36
Yetim, A., Yetim, Ç., Baş, F., Erol, O. B., Çığ, G., Uçar, A., & Darendelıler, F. (2016) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.3253 · Cited by 36
Ollila, M., West, S., Keinänen-Kiukaaniemi, S., Jokelainen, J. J., AUVINEN, J. P., Puukka, K. S., Ruokonen, A., Järvelin, M., Tapanainen, J. S., Franks, S., et al. (2017) · Human Reproduction · doi:10.1093/humrep/dex030 · Cited by 37
Steroid Mass Spectrometry for the Diagnosis of PCOS
Keevil, B. G. (2019) · Medical Sciences · doi:10.3390/medsci7070078 · Cited by 36
“The diagnosis of polycystic ovarian syndrome (PCOS) is usually based on the Rotterdam criteria and relies on at least two out of the following: polycystic ovaries, ovulatory dysfunction, and hyperandrogenism [1].”
MethodInfluentialMarinkovic-Radosevic, J., Cigrovski Berkovic, M., Kruezi, E., Bilic-Curcic, I., & Mrzljak, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.932 · Cited by 35
Zuuren, E. J., & Fedorowicz, Z. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14486 · Cited by 35
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
“Based on the available limited data, use of statins is not routinely recommended in women with PCOS unless they meet current indications for statin therapy [23].”
BackgroundThe free androgen index is inaccurate in women when the SHBG concentration is low
Keevil, B. G., Adaway, J., Fiers, T., Moghetti, P., & Kaufman, J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13561 · Cited by 35
Stem Cells and Infertility: A Review of Clinical Applications and Legal Frameworks
Cucinella, G., Gullo, G., Catania, E., Perino, A., Billone, V., Marinelli, S., Napoletano, G., & Zaami, S. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14020135 · Cited by 35
“There is another disorder linked to irregular menstruation, obesity, atypical hair growth, and infertility: polycystic ovarian syndrome [52].”
BackgroundGonadal dysfunction in women with diabetes mellitus
Zaimi, M., Michalopoulou, O., Stefanaki, K., Kazakou, P., Vasileiou, V., Ψαλτοπούλου, Θ., Karagiannakis, D. S., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-03729-z · Cited by 35
Henney, A. E., Gillespie, C. S., LAI, J., Schofield, P. G., Riley, D. R. J., Caleyachetty, R., Barber, T. M., Miras, A. D., Dobbie, L. J., Hughes, D. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae481 · Cited by 36
Amato, M. C., Magistro, A., Gambino, G., Vesco, R., & Giordano, C. S. D. S. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0600 · Cited by 35
“It is known that women with PCOS (12), in which they recommend the use of an oral glucose tolerance test (OGTT) (fasting and a 2-h glucose level using a 75 g oral glucose load) to screen for IGT and T2DM in all adolescents and adult women with PCOS because they are at high risk for such…”
Abu-Hijleh, T. M., Gammoh, E., Al-Busaidi, A. S., Malalla, Z. H., Madan, S., Mahmood, N., & Almawi, W. Y. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000441570 · Cited by 31
Liao, W., Chiang, J., Li, C.-J., Lee, M.-T., Su, C.-C., & Yen, H. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7070179 · Cited by 36
“With regard to pharmaceutical treatments, oral contraceptives (OCs) are suggested as a first-line therapy for menstrual irregularities and hyperandrogenism [10,11].”
BackgroundAmiri, M., Nahidi, F., Yarandi, R. B., Khalili, D., Tohidi, M., & Tehrani, F. R. (2020) · Human Reproduction · doi:10.1093/humrep/dez255 · Cited by 35
Puberty in the Female and Its Disorders
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00016-6 · Cited by 38
Torres-Zegarra, C., Sundararajan, D., Benson, J., SEAGLE, H. M., Witten, M., Walders‐Abramson, N., Simon, S. L., Huguelet, P. S., Nokoff, N., & Cree‐Green, M. (2021) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2021.02.002 · Cited by 35
Shahdadian, F., Ghiasvand, R., Abbasi, B., Feizi, A., Saneei, P., & Shahshahan, Z. (2019) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2018-0145 · Cited by 30
Diagnosis, Management, and Associated Comorbidities of Polycystic Ovary Syndrome: A Narrative Review
Choudhari, R. G., Tayade, S. A., Tiwari, A., & Satone, P. D. (2024) · Cureus · doi:10.7759/cureus.58733 · Cited by 34
“Mainly in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and in vitro manipulation (IVM) are tried [9,51].”
BackgroundHuang, X., Geng, H., Liang, C., Xiong, X., Du, X., Zhuan, Q., Liu, Z., Lin, M., Zhou, D., Zhang, L., et al. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.11.021 · Cited by 34
Polycystic ovarian syndrome: A review covering phytoconstituents for its outstrip management
Joshi, M., Shankar, R., Pathak, K., & Yadav, R. (2021) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2021.100011 · Cited by 34
Harris, R. A., McAllister, J. M., & Strauss, J. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310611 · Cited by 34
“The diagnosis of PCOS was made according to the National Institutes of Health (NIH) consensus guidelines [9,10], which include hyperandrogenemia/hyperandrogenism and oligo-ovulation and the exclusion of other causes of hyperandrogenemia (e.”
MethodDiabetes detection in women with gestational diabetes and polycystic ovarian syndrome
Hanna, F., Wu, P., Heald, A. H., & Fryer, A. A. (2023) · BMJ · doi:10.1136/bmj-2022-071675 · Cited by 35
Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment
Spritzer, P. M., & Motta, A. B. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12719 · Cited by 34
Physical Examination Findings Among Children and Adolescents With Obesity: An Evidence-Based Review
Armstrong, S., Lazorick, S., Hampl, S. E., Skelton, J. A., Wood, C. T., Collier, D. N., & Perrin, E. M. (2016) · PEDIATRICS · doi:10.1542/peds.2015-1766 · Cited by 34
Normal Pubertal Development in Daughters of Women With PCOS: A Controlled Study
Legro, R. S., Kunselman, A. R., Stetter, C., Gnatuk, C. L., Estes, S. J., Brindle, E., Vesper, H. W., Botelho, J. C., Lee, P. A., & Dodson, W. C. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2707 · Cited by 34
Self-citationJin, L., Yang, Q., Zhou, C., Liu, L., Wang, H. H., Hou, M., Wu, Y., Shi, F.-T., Sheng, J., & Huang, H. (2018) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2018.08.005 · Cited by 34
Carreau, A., Pyle, L. L., Garcia‐Reyes, Y., Rahat, H., Vigers, T., Jensen, T., Scherzinger, A. L., Nadeau, K. J., & Cree‐Green, M. (2019) · Clinical Endocrinology · doi:10.1111/cen.14062 · Cited by 35
Tharayil, S. P., & Shukla, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136233 · Cited by 33
“In comparison, GLP-1 receptor agonists such as exenatide and liraglutide result in modest weight loss women with PCOS by reducing inflammatory cytokines and improve sex hormone abnormalities, insulin sensitivity, and the menstrual cycle to even greater extent than metformin [184].”
The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment
Liu, Y. T., Liu, F., Cao, L., Li, X., Gu, W. T., Zheng, Y. Z., Tang, H., Wang, Y., Yao, H. W., Zhang, Y., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02180-4 · Cited by 33
Carbajal-García, A., Reyes-García, J., & Montaño, L. M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/8849641 · Cited by 34
“PCOS is one of the most common endocrine disorders affecting women of reproductive age [205].”
BackgroundBrown adipose tissue activation with ginsenoside compound K ameliorates polycystic ovary syndrome
Ye, R., Yan, C., Zhou, H., Zhang, C., Huang, Y., Dong, M., Zhang, H., Lin, J., Jiang, X., Yuan, S., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15909 · Cited by 33
“…Criteria diagnosis of PCOS is based on 2 of the 3 Rotterdam Criteria which are:- 1. hyperandrogenism; 2. ovulation disfunction and 3, polycystic ovaries on ultrasound and the exclusion of phenotypically similar androgen excess disorders such as congenital adrenal hyperplasia (Legro et al., 2013).”
BackgroundMethodPolycystic In Ovarian Syndrome And Its Various Treatment Strategies
Maqbool, M., Nasir, N., & Mustafa, S. (2018) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.1412697 · Cited by 35
Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis
Cai, X., Qiu, S., Li, L., Zügel, M., Steinacker, J. M., & Schümann, U. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.10.114 · Cited by 33
The obesogen tributyltin induces features of polycystic ovary syndrome (PCOS): a review
Merlo, E., Silva, I. V., Cardoso, R. C., & Graceli, J. B. (2018) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2018.1496214 · Cited by 34
“Thus, women with PCOS and metabolic risk factors and/or insulin resistance may be screened using serum markers of liver dysfunction (Legro et al. 2013).”
BackgroundInfluentialLazaridou, S., Dinas, K. D., & Τζιόμαλος, Κ. (2017) · HORMONES · doi:10.14310/horm.2002.1757 · Cited by 34
Managing polycystic ovary syndrome in primary care
Lua, A., How, C. H., & King, T. (2018) · Singapore Medical Journal · doi:10.11622/smedj.2018135 · Cited by 33
Minimal difference in phenotype between adolescents and young adults with polycystic ovary syndrome
Zore, T., Lizneva, D., Brakta, S., Walker, W., Сутурина, Л. В., & Azziz, R. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.10.020 · Cited by 34
Kałużna, M., Czlapka-Matyasik, M., Kompf, P., Moczko, J., Wachowiak-Ochmańska, K., Janicki, A., Samarzewska, K., Ruchała, M., & Ziemnicka, K. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211066699 · Cited by 32
Carbohydrate Intake Prior to Oral Glucose Tolerance Testing
Klein, K. R., Walker, C. P., McFerren, A. L., Huffman, H., Frohlich, F., & Buse, J. B. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab049 · Cited by 32
“The Endocrine Society also recommends use of OGTT over HbA1c in women with polycystic ovarian syndrome, given the association between IGT and cardiovascular disease in women (46).”
MethodWalker, K. A. B., DeCherney, A. H., & Saunders, R. D. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000596 · Cited by 32
Tsukui, Y., Kitahara, Y., Hasegawa, Y., Kobayashi, M., Osuka, S., & Iwase, A. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0081 · Cited by 33
Polycystic Ovarian Syndrome in Adolescents
Adone, A., & Fulmali, D. G. (2023) · Cureus · doi:10.7759/cureus.34183 · Cited by 32
“Myoinositol efficiently brings about normal ovarian function and improves the fetus's ovum and quality [11].”
BackgroundSoares, J. M., Hayashida, S. A. Y., Marcondes, J. A. M., Maciel, G. A. R., Barcellos, C. R. G., Maffazioli, G. D. N., Monteiro, K. K. A. C., Turri, J. A. O., Azziz, R., & Baracat, E. C. (2023) · Biomedicines · doi:10.3390/biomedicines11123262 · Cited by 32
“Thus, periodic T2DM screening for PCOS women is recommended [14–16].”
BackgroundPasquali, R., Diamanti‐Kandarakis, E., & Gambineri, A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0374 · Cited by 32
Self-citationWei, D., Zhang, B., Shi, Y., Zhang, L., Zhao, S., Du, Y., Xu, L., Legro, R. S., Zhang, H., & Chen, Z. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01294 · Cited by 32
Self-citationDo Different Diagnostic Criteria Impact Polycystic Ovary Syndrome Diagnosis for Adolescents?
Akgül, S., Düzçeker, Y., Kanbur, N., & Derman, O. (2017) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2017.12.002 · Cited by 33
What is adolescent polycystic ovary syndrome?
Peña, A. S., & Metz, M. P. (2017) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.13821 · Cited by 32
Polak, A. M., Krentowska, A., Łebkowska, A., Buczyńska, A., Adamski, M., Adamska-Patruno, E., Fiedorczuk, J., Krętowski, A. J., Kowalska, I., & Adamska, A. (2020) · Nutrients · doi:10.3390/nu12092753 · Cited by 31
“Polycystic ovary syndrome is diagnosed by the presence of at least two of the following criteria: oligoovulation and/or anovulation, clinical and/or biochemical hyperandrogenism, and a polycystic ovarian morphology in a transvaginal ultrasound [2].”
BackgroundInfluentialSoares, N. P., Santos, A. C. S. D., Costa, E. C., Azevedo, G. D., Damasceno, D. C., Fayh, A. P. T., & Lemos, T. M. A. M. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000444130 · Cited by 31
Targher, G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1610000 · Cited by 40
Dhesi, A. S., Murtough, K. L., Lim, J. K., Schulkin, J. A., McGovern, P. G., Power, M. L., & Morelli, S. S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.07.043 · Cited by 31
Tang, X., Sun, Z., & Gong, L. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13462 · Cited by 31
Hawley, J. M., Adaway, J., Owen, L. J., & Keevil, B. G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0959 · Cited by 31
Qu, J., Li, B., Qiu, M., Wang, J., Chen, Z., Li, K., & Teng, X. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06686-y · Cited by 31
“Due to the similarity of normal pubertal development and features of PCOS, how PCOS should be defined is no general consensus for adolescents [5, 6].”
BackgroundNon-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones
Arefhosseini, S., Ebrahimi‐Mameghani, M., Najafipour, F., & Tutunchi, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032361 · Cited by 31
ElMonier, A. A., El-Boghdady, N. A., Fahim, S. A., Sabry, D., Elsetohy, K. A., & Shaheen, A. A. (2023) · Non-coding RNA Research · doi:10.1016/j.ncrna.2023.02.008 · Cited by 31
“Polycystic ovary syndrome (PCOS) represents one of the most common heterogenous reproductive and metabolic disorders affecting about 5–10% of women during their reproductive age and 75% of the anovulatory infertility worldwide [1,2].”
BackgroundReinehr, T., Kulle, A. E., Rothermel, J., Knop, C., Lass, N., Bosse, C., & Holterhus, P. (2017) · Clinical Endocrinology · doi:10.1111/cen.13358 · Cited by 31
Ramos, C. O., Latronico, A. C., Cukier, P., Macedo, D. B., Bessa, D. D. S., Cunha-Silva, M., Arnhold, I. J. P., Mendonca, B. B., & Brito, V. N. (2017) · Neuroendocrinology · doi:10.1159/000477584 · Cited by 31
(2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1418853 · Cited by 30
“The diagnosis of PCOS was based on all three diagnostic criteria of the Rotterdam consensus, namely clinical and biochemical evidence of hyperandrogenemia (Ferriman-Gallwey score (FGS), free androgen index (FAI), respectively), oligomenorrhea or amenorrhea and polycystic ovaries on transabdominal ultrasound [4,5].”
MethodRetractedThe value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome
Kyritsi, E. M., Dimitriadis, G. K., Angelousi, A. G., Mehta, H., Shad, A., Mytilinaiou, M. G., Kaltsas, G., & Randeva, H. S. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12961 · Cited by 31
Endocrine and Reproductive Effects of Polycystic Ovarian Syndrome
Ecklund, L. C., & Usadi, R. (2014) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2014.09.003 · Cited by 31
Amini, L., Mojab, F., Jahanfar, S., Sepidarkish, M., Raoofi, Z., & Maleki-Hajiagha, A. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102245 · Cited by 30
Antonio, L., Pauwels, S., Laurent, M. R., Vanschoubroeck, D., Jans, I., Billen, J., Claessens, F., Decallonne, B., De Neubourg, D., Vermeersch, P., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/7956951 · Cited by 30
“Patients were classified as having PCOM if they had ≥12 antral follicles (2–9mm in diameter) in both ovaries and/or an ovarian volume> 10mL in one or two ovaries [4, 23].”
BackgroundMethodInfluentialCutaneous manifestations of polycystic ovary syndrome
Carmina, E. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.015 · Cited by 30
Polycystic ovary Syndrome in Adolescents: Pitfalls in Diagnosis and Management
Kostopoulou, E., Anagnostis, P. G., Bosdou, J. Κ., Spiliotis, B. E., & Goulis, D. G. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00388-9 · Cited by 30
Stasi, V. D., Maseroli, E., Rastrelli, G., Scavello, I., Cipriani, S., Todisco, T., Marchiani, S., Sorbi, F., Fambrini, M., Petraglia, F., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.641446 · Cited by 30
Diagnosis experiences of adolescents with polycystic ovary syndrome: Cross‐sectional study
Peña, A. S., Teede, H. J., Hewawasam, E., Hull, M. L., & Gibson‐Helm, M. E. (2021) · Clinical Endocrinology · doi:10.1111/cen.14604 · Cited by 30
Circulating Galectin-3 levels in women with polycystic ovary syndrome: A meta-analysis
Bahreiny, S. S., Bastani, M., Aghaei, M., Dabbagh, M. R., & Mahdizade, A. H. (2024) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2023.10.003 · Cited by 30
Zuchelo, L. T. S., Alves, M. S., Baracat, E. C., Sorpreso, I. C. E., & Soares, J. M. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2360077 · Cited by 30
Utility of ultrasound in the diagnosis of polycystic ovary syndrome in adolescents
Youngster, M., Ward, V. L., Blood, E., Barnewolt, C. E., Emans, S. J., & DiVasta, A. D. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.07.1241 · Cited by 30
Optimal management of polycystic ovary syndrome in adolescence
Baldauff, N. H., & Arslanian, S. A. (2015) · Archives of Disease in Childhood · doi:10.1136/archdischild-2014-306471 · Cited by 30
Self-citationOptimizing reproductive health in women with obesity and infertility
Belan, M., Harnois-Leblanc, S., Laferrère, B., & Baillargeon, J.-P. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.171233 · Cited by 29
Kempná, P., Marti, N., Udhane, S., & Flück, C. E. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.12.015 · Cited by 29
Рыкова, О. В. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.8.72.2015.72340 · Cited by 29
Fu, L.-W., Gao, Z., Zhang, N., Yang, N., Long, H.-Y., Kong, L.-Y., & Li, X. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117698 · Cited by 30
Tedesco, S., Adorni, M. P., Ronda, N., Cappellari, R., Mioni, R., Barbot, M., Pinelli, S., Plebani, M., Bolego, C., Scaroni, C. M., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01911-2 · Cited by 29
Depression in Girls With Obesity and Polycystic Ovary Syndrome and/or Type 2 Diabetes
Benson, J., Severn, C., Hudnut‐Beumler, J., Simon, S. L., Walders‐Abramson, N., Shomaker, L. B., Gulley, L. D., Taylor, A., Kelsey, M. M., Nadeau, K. J., et al. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.05.015 · Cited by 29
Giri, A., Joshi, A., Shrestha, S., & Chaudhary, A. (2022) · Journal of Nepal Medical Association · doi:10.31729/jnma.7221 · Cited by 29
Clinical guidelines «Polycystic Ovary Syndrome»
Adamyan, L. V., Andreeva, E. N., Absatarova, Y. S., Grigoryan, O. R., Dedov, I. I., Mel'nichenko, G. A., Сутурина, Л. В., Филиппов, О. С., Sheremetyeva, E. V., Евгеньевна, Ч. Г., et al. (2022) · Problems of Endocrinology · doi:10.14341/probl12874 · Cited by 31
Zou, Y., Liao, R., Cheng, R., Chung, H., Zhu, H., & Huang, Y. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106370 · Cited by 29
Very low-calorie ketogenic diet (VLCKD): a therapeutic nutritional tool for acne?
Verde, L., Frías-Toral, E., Cacciapuoti, S., Simancas‐Racines, D., Megna, M., Caiazzo, G., Potestio, L., Maisto, M., Tenore, G. C., Colao, A., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05119-5 · Cited by 30
Song, D. K., Lee, H., Sung, Y., & Oh, J. Y. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.6.1404 · Cited by 29
“The routine use of an oral glucose tolerance test (OGTT) is recommended for screening for IGT and T2DM in women with PCOS.(5,6) However, OGTT is time-consuming and labor intensive because venous blood samples are required after an overnight fasting and at 120 min after administration of a glucose solution.”
MethodWorldwide Dissatisfaction With the Diagnostic Process and Initial Treatment of PCOS
(2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3808 · Cited by 19
Ezeh, U. I., Huang, A., Landay, M., & Azziz, R. (2018) · Journal of Women s Health · doi:10.1089/jwh.2017.6833 · Cited by 29
“Currently, the decision to treat hirsutism is largely based on the recommendation of various professional organizations.(3,37,38) These recommendations generally note that prolonged medical therapy of at least 6–12 months of duration is necessary for suppression of hirsutism, a recommendation based on the hair follicl…”
BackgroundBusiah, K., Colmenares, A., Bidet, M., Tubiana‐Rufi, N., Lévy‐Marchal, C., Delcroix, C., Jacquin, P., Martin, D., Benadjaoud, L., Jacqz-Aigrain, É., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000471805 · Cited by 29
Polycystic ovary syndrome: An update
Pfieffer, M. L. (2019) · Nursing · doi:10.1097/01.nurse.0000569748.65796.d1 · Cited by 29
Polycystic ovary syndrome: controversies and challenges
Soares, J. M., Baracat, M. C. P., Maciel, G. A. R., & Baracat, E. C. (2015) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.61.06.485 · Cited by 29
Altinok, M. L., Ravn, P., Andersen, M., & Glintborg, D. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1460343 · Cited by 28
Metadata
- Authors
- Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4565-4592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5399492
- OpenAlex
- W2120973019
- Cited by
- 1,919
- References
- 356
- Citations by year
- 2026: 104 · 2025: 135 · 2024: 149 · 2023: 181 · 2022: 207 · 2021: 197 · 2020: 149 · 2019: 160 · 2018: 145 · 2017: 129 · 2016: 131 · 2015: 124 · 2014: 95 · 2013: 6
- FWCI
- 143.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020595, P30DK020595)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065029)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, Rotterdam criteria, hyperandrogenism, ovulatory dysfunction, PCOS treatment, hormonal contraception, clomiphene citrate, metformin, insulin resistance, menstrual irregularity, hirsutism, acne, infertility, adolescents, menopausal women, weight loss, lifestyle intervention, thiazolidinediones, statins, cardiovascular risk
- MeSH terms
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Polycystic Ovary Syndrome, Societies, Scientific, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.